According to a recent LinkedIn post from Truveta, the company’s researchers presented real-world evidence on the use of Alzheimer’s therapy lecanemab at AMCP 2026. The post cites six‑month adherence of 62.7% overall, with adherence rising from 16.7% in 2023 to 64.5% in 2025, alongside analysis of MRI monitoring patterns in treated patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Truveta is positioning its data platform as a tool for understanding how novel therapies are adopted and managed outside clinical trials. For investors, this emphasis on real‑world evidence in a high‑profile therapeutic area could enhance Truveta’s relevance to biopharma, payers, and providers, potentially supporting demand for its analytics offerings and strengthening its competitive standing in healthcare data and outcomes research.